Our Pipeline
The IMA’s thriving pipeline of projects includes projects aimed at prototyping innovative medicines and vaccines (Drug and Vaccine Prototyping) as well projects aimed at studying human patients (Experimental Human Biology). Representative projects include those in the pipeline below.
Drug and Vaccine Prototyping
The Drug and Vaccine Prototyping arm helps Stanford faculty convert their scientific discoveries into high-quality drug and vaccine prototypes. Such prototypes will be embraced by industry because they reduce the therapeutic risk inherently associated with new biology while rapidly identifying those discoveries that have the best chance of improving patient care. Prototyping on this scale has never been attempted in an academic setting before.
Experimental Human Biology
The Experimental Human Biology arm helps lab researchers leverage Stanford’s hospitals and clinics to gain access to critical data and/or reagents to test the therapeutic potential of their scientific hypotheses and discoveries more rapidly. Patient-facing research is especially crucial in the development of treatments for emerging or rare diseases.
Click on a project title below for more details.
Legend:
Partnered
Project Title
Lead ID
Lead Optimization
IND-Enabling
Small Molecule Therapeutics
Cell / Gene Therapies
Protein Therapeutics
Clinical Studies
Theranostic TG2 inhibitor for celiac disease
E3 ubiquitin ligase activation for the treatment of pancreatic cancer
Fluoxetine analog for glioblastoma therapy
Mutant-selective inhibitor for JAK2-dependent cancers
Inhibitors of NaDC1 for Prevention of Kidney Stones
Novel therapeutic for Parkinson’s disease
Chloride channel inhibitor for hyponatremia
BMP synthase activator for neurodegeneration
RARalpha antagonist for neuropathic pain prevention
AAV gene therapy for chronic pain
CRISPR-corrected esophageal cell therapy for epidermolysis bullosa
Gene editing for HIV
NMNAT2 AAV gene therapy for glaucoma
AAV gene therapy for dilated cardiomyopathy
Tri-specific CAR T-cell therapy for medulloblastoma
Broad-spectrum coronavirus antibody
CNTN2 selective antibody-guided cardiac surgery
Reversal agent for T-cell depleting antibodies
Chemokine receptor antagonist for glioblastoma therapy
ISM1 derivative for NASH therapy
Our pipeline embraces projects founded on four essential criteria
Solving an Unmet Medical Need
Solutions with potential to address pressing medical gaps.
First-in-Class Potential
Direct pathways to novel, pioneering medicines.
Highly Differentiated
Capacity to introduce innovative approaches across disease spectrums.
Leveraging Expertise
Builds upon the deep expertise of Stanford’s scientists and physicians.
Success Stories
Projects supported by the IMA have the potential to transform medicine. Learn about some of the products that exited our pipeline.
Pediatric matched stem cell and organ transplant therapy
Entrepreneur-in-residence launches cancer biotech
New company tricks cancer cells into self-destructing
Nobel laureate launches startup for new cancer immunotherapy
New hope from old drugs for cystic fibrosis: startup explores combination therapy
New depression biomarker enables clinical trial in precision therapies
COVID-19 study sparks new company exploring first-in-class medicines for rare pulmonary diseases
New stable and affordable COVID vaccine could revolutionize global vaccine distribution
